A report of resources used by clinicians in the UK to support motor neuron disease genomic testing
- PMID: 38164895
- PMCID: PMC11262425
- DOI: 10.1080/21678421.2023.2299204
A report of resources used by clinicians in the UK to support motor neuron disease genomic testing
Abstract
Genetic testing is a key decision-making point for people with motor neuron disease (MND); to establish eligibility for clinical trials, better understand the cause of their condition, and confirm the potential risk to relatives, who may be able to access predictive testing. Given the wide-reaching implications of MND genetic and predictive testing, it is essential that families are given adequate information, and that staff are provided with appropriate training. In this report we overview the information resources available to people with MND and family members around genetic testing, and the educational and training resources available to staff, based on information obtained through a freedom of information request to UK-based NHS Trusts. MND Association resources were most commonly used in information sharing, though we highlight distinctions between neurology and genetics centers. No respondents identified comprehensive training around MND genetic testing. We conclude with practice implications and priorities for the development of resources and training.
Keywords: Genetics; patient information; training.
Conflict of interest statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Similar articles
-
Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.Eur J Hum Genet. 2025 Jan;33(1):7-13. doi: 10.1038/s41431-024-01718-4. Epub 2024 Nov 5. Eur J Hum Genet. 2025. PMID: 39501102 Free PMC article. Review.
-
A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning.Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):405-413. doi: 10.1080/21678421.2022.2150556. Epub 2022 Dec 2. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36458618
-
Neurologists' understanding of reproductive medicine options for genetic forms of motor neuron disease.Amyotroph Lateral Scler Frontotemporal Degener. 2025 May;26(3-4):331-342. doi: 10.1080/21678421.2024.2416677. Epub 2024 Oct 18. Amyotroph Lateral Scler Frontotemporal Degener. 2025. PMID: 39422440 Free PMC article.
-
Genetic testing in motor neuron disease and frontotemporal dementia: a 5-year multicentre evaluation.J Med Genet. 2022 Jun;59(6):544-548. doi: 10.1136/jmedgenet-2021-107776. Epub 2021 May 7. J Med Genet. 2022. PMID: 33963046
-
Familial motor neuron disease: co-occurrence of PLS and ALS (-FTD).Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):53-60. doi: 10.1080/21678421.2023.2255621. Epub 2023 Sep 7. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 37679883 Review.
Cited by
-
Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.Eur J Hum Genet. 2025 Jan;33(1):7-13. doi: 10.1038/s41431-024-01718-4. Epub 2024 Nov 5. Eur J Hum Genet. 2025. PMID: 39501102 Free PMC article. Review.
-
Genomic sequencing technologies for rare disease in mainstream healthcare: the current state of implementation.Eur J Hum Genet. 2025 Aug 22. doi: 10.1038/s41431-025-01925-7. Online ahead of print. Eur J Hum Genet. 2025. PMID: 40846792 Review.
References
-
- NICE . Shared decision making, NICE guideline. June 17, 2021. Available at: https://www.nice.org.uk/guidance/ng197. Accessed November 27, 2023.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical